Devicor Announces CE Mark Approval For Mammotome® revolve™ Biopsy System

Devicor Announces CE Mark Approval For Mammotome® revolve™ Biopsy System PR Newswire CINCINNATI, Dec. 18, 2012 - Featuring patented DualVac™ technology and patented specimen management system CINCINNATI, Dec. 18, 2012 /PRNewswire/ -- Devicor® Medical Products, Inc. (Devicor) announced today that it has completed the necessary steps to place CE Mark on Mammotome® revolve™, its new dual vacuum-assisted biopsy system. The product has also received approval from the United States Food and Drug Administration. Mammotome® revolve™ is the next generation biopsy system, leveraging the clinician and pathologist valued benefits of the original Mammotome® system to provide high-quality tissue specimens, now enhanced in the new system with innovative features to provide further procedural efficiency and ease of use. Mammotome® revolve™ features an advanced specimen management system capable of collecting and organizing high-quality individual tissue samples in numbered, specimen radiograph and pathology-ready chambers that preserve tissue integrity. The system also features patented DualVac™ vacuum technology that gives clinicians the ability to secure larger contiguous tissue samples. These features in combination with a doctor-controlled variable aperture allow clinicians to confirm or adjust sample acquisition in response to procedural situations to confidently access and acquire challenging lesions. An additional benefit is the efficiency of pre-biopsy planning time.